Kaskela Law LLC Announces Stockholder Investigation of Apyx Medical Corp. (APYX) and Encourages Long-Term APYX Stockholders to Contact the Firm

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

May 23, 2020 08:00 am

Kaskela Law LLC is investigating Apyx Medical Corporation (NASDAQ: APYX) (“Apyx” or the “Company”) on behalf of the Company’s stockholders.

In September 2019, a securities fraud complaint was filed against Apyx in federal court on behalf of certain purchasers of Apyx’s common stock. Among other things, the complaint alleged that Apyx violated the federal securities laws by making a series of materially false and misleading statements to investors between December 2018 and April 2019 concerning Apyx’s business, operations, and prospects.

As detailed in the complaint, on December 21, 2018, Apyx announced that it had submitted a 510(k) application for regulatory clearance with the FDA for the use of J-Plasma (a patented helium-based plasma surgical product) for dermal resurfacing based on the results of a clinical study. Also on that day, Apyx’s CEO stated: “We were very pleased with the clinical results of this study and we are optimistic in receiving regulatory clearance for this differentiated technology in 2019.”

However, on April 1, 2019, Apyx announced that it had withdrawn its application for regulatory clearance and disclosed that the study had failed to meet its primary efficacy endpoint. Additionally, the Company revealed that one of three investigational centers used in the study had deviated from protocol by prescribing a steroid to its patients. Following this news, shares of the Company’s stock declined $2.49 per share, or nearly 36% in value, to close at $4.46 per share on April 2, 2019.

The investigation seeks to determine whether the members of Apyx’s board of directors breached their fiduciary duties in connection with the above.

Current Apyx stockholders who purchased or acquired shares of the Company’s stock prior to December 21, 2018 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 – 1585, or via email at skaskela@kaskelalaw.com or online at http://kaskelalaw.com/case/apyx-medical-corp/, to discuss this investigation and their legal rights and options.

Kaskela Law LLC represents investors in securities fraud, corporate governance, and merger & acquisition litigation. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com. This notice may constitute attorney advertising in certain jurisdictions.

D. Seamus Kaskela, Esq.
(484) 258 – 1585
(888) 715 – 1740

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).